Why Appendix Cancer Needs Its Own Treatments: Insights from ASCO Daily News

Appendix cancer has often been treated like colorectal cancer (CRC). A recent article in ASCO Daily News by Dr. John Paul Shen, a member of ACPMP’s Medical Advisory Board, and Dr. Michael B. Foote, explains why that approach deserves a closer look – and what it means for appendix cancer chemotherapy and future treatment.

Key differences between appendix and colorectal cancer

The authors highlight several important ways appendiceal adenocarcinoma differs from CRC:

• Molecular profile: Appendix cancer has its own pattern of genetic changes, frequently involving genes such as KRAS, GNAS, and TP53, while colorectal cancer commonly involves APC.
• How the disease behaves: Appendix cancer frequently spreads within the abdomen (peritoneum) and often follows a different course than CRC.
• Response to chemotherapy: Standard CRC chemotherapy may not work the same way in appendix cancer, and the evidence supporting it is limited.

A growing focus on appendix-specific research

Several clinical trials are now focused on developing therapies specifically for appendix cancer, and some studies of targeted and immune-based treatments have shown encouraging results compared with standard CRC treatments. Rethinking how appendix cancer is treated is key to improving patient outcomes and advancing drug development for this rare disease.

Read the article

Shen JP, Foote MB. Appendix Cancer Is Not the Same as Colorectal Cancer: Implications for Systemic Chemotherapy. ASCO Daily News. March 27, 2025. Read the full article.

Looking for clinical trials? Visit ACPMP’s Clinical Trials Database.

This summary is for general information only and is not medical advice. Please talk with your care team about what this research may mean for you.